{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:50:29Z","timestamp":1793749829874,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015237","name":"The Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jacc.2024.07.045","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T10:03:46Z","timestamp":1728295426000},"page":"1512-1524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Bivalirudin vs Heparin Anticoagulation in\u00a0STEMI"],"prefix":"10.1016","volume":"84","author":[{"given":"Gregg W.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erlinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod H.","family":"Stables","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Frigoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-5096","authenticated-orcid":false,"given":"Ghazaleh","family":"Mehdipoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-4451","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Redfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.07.045_bib1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.mayocp.2016.06.013","article-title":"Antithrombotic approaches in acute coronary syndromes: optimizing benefit vs bleeding risks","volume":"91","author":"Singh","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2024.07.045_bib2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jcin.2016.09.023","article-title":"Bleeding versus ischemic events: using all-cause mortality to identify a preferred antithrombotic strategy","volume":"9","author":"Bittl","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.07.045_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.109.878017","article-title":"Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial","volume":"121","author":"Pocock","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.07.045_bib4","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.amjcard.2007.06.026","article-title":"Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial","volume":"100","author":"Feit","year":"2007","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.jacc.2024.07.045_bib5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/CIRCULATIONAHA.122.061527","article-title":"Impact on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: a meta-analysis of individual patient data from seven multicenter randomized clinical trials","volume":"146","author":"Gargiulo","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.07.045_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcin.2010.10.011","article-title":"Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention","volume":"4","author":"Verheugt","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.07.045_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001645","article-title":"Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis","volume":"8","author":"Kwok","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.07.045_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4244\/EIJV8I1A12","article-title":"Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction","volume":"8","author":"Vranckx","year":"2012","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2024.07.045_bib9","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.07.045_bib10","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.07.045_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0039-1700872","article-title":"Individual patient data pooled analysis of randomized trials of bivalirudin versus heparin in acute myocardial infarction: rationale and methodology","volume":"120","author":"Bikdeli","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2024.07.045_bib13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"6982","key":"10.1016\/j.jacc.2024.07.045_bib15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/bmj.310.6982.751","article-title":"Magnesium in acute myocardial infarction","volume":"310","author":"Yusuf","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2024.07.045_bib16","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.07.045_bib17","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.07.045_bib18","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.07.045_bib19","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.07.045_bib20","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.07.045_bib21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.07.045_bib22","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.07.045_bib23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jacc.2024.07.045_bib24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","article-title":"Bivalirudin versus heparin during PCI in NSTEMI: individual patient data meta-analysis of large randomized trials","volume":"148","author":"Bikdeli","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.07.045_bib25","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.116.023359","article-title":"Should a reduction in all-cause mortality be the goal when assessing preventive medical therapies?","volume":"135","author":"Sasieni","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.07.045_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacc.2013.09.027","article-title":"Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: the HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.07.045_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2014.10.029","article-title":"Bivalirudin versus heparin with or without glycoprotein IIb\/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials","volume":"65","author":"Stone","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.07.045_bib28","first-page":"307","article-title":"Anticoagulation in ST-elevation myocardial infarction","volume":"10","author":"Bavishi","year":"2021","journal-title":"Interv Cardiol Clin"},{"key":"10.1016\/j.jacc.2024.07.045_bib29","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.thromres.2015.06.001","article-title":"Risk of stent thrombosis and major bleeding with bivalirudin compared with active control: a systematic review and meta-analysis of randomized trials","volume":"136","author":"Kianoush","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2024.07.045_bib30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.07.045_bib31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4330\/wjc.v9.i9.761","article-title":"Safety, efficiency and cost effectiveness of bivalirudin: A systematic review","volume":"9","author":"Mehrzad","year":"2017","journal-title":"World J Cardiol"},{"key":"10.1016\/j.jacc.2024.07.045_bib32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1160\/TH09-05-0287","article-title":"Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analysis of randomised trials","volume":"102","author":"De Luca","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2024.07.045_bib33","first-page":"1240","article-title":"Meta-analysis of bivalirudin versus heparin in transradial coronary interventions","volume":"96","author":"Kheiri","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.07.045_bib34","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.jcin.2016.09.020","article-title":"Use and effectiveness of bivalirudin versus unfractionated heparin for percutaneous coronary intervention among patients with ST-elevation myocardial infarction in the United States","volume":"10","author":"Secemsky","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2024.07.045_bib35","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/ehjcvp\/pvad029","article-title":"Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome","volume":"9","author":"Galli","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"10.1016\/j.jacc.2024.07.045_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001855","article-title":"Individual participant data (IPD) meta-analyses of randomised controlled trials: guidance on their use","volume":"12","author":"Tierney","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2024.07.045_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724081932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724081932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:15:53Z","timestamp":1760591753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724081932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0735109724081932"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.07.045","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bivalirudin vs Heparin Anticoagulation in\u00a0STEMI","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.07.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}